-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
-
Summary
-
Ambrx Biopharma Cayman, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q1 2022 to Q2 2023.
- Ambrx Biopharma Cayman, Inc. Nonoperating Income (Expense) for the quarter ending June 30, 2023 was $1.65M, a 2325% increase year-over-year.
- Ambrx Biopharma Cayman, Inc. annual Nonoperating Income (Expense) for 2022 was $342K.
- Ambrx Biopharma Cayman, Inc. annual Nonoperating Income (Expense) for 2021 was -$3.86M, a 18.2% increase from 2020.
- Ambrx Biopharma Cayman, Inc. annual Nonoperating Income (Expense) for 2020 was -$4.72M, a 3108% decline from 2019.
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)